The Role of NSAIDs in Osseointegration of Dental Implants
The Principal Investigator is Dr. Ryan E. Tomlinson, PhD, Assistant Professor of Orthopaedic Surgery at Thomas Jefferson University. His research in bone repair has yielded substantial acclaim in the field, including the Harold M. Frost Young Investigator Award, the Endocrine Fellows Foundation Award, the ASBMR Young Investigator Award, and the IBMS Alice L. Jee Young Investigator Award. The Co-Principal Investigators are Dr. Robert Diecidue, DMD, MD, MBA, MSPH, Professor and Chair; and Dr. Daniel Taub, DDS, MD, Associate Professor and Vice-Chair of the Department of Oral and Maxillofacial Surgery at Thomas Jefferson University, both accomplished physician-scientists in the field of oral surgery.
This study on the role of NSAIDs in dental implant osseointegration is divided into two specific aims, for new implants (Aim 1) and failed implants (Aim 2). In Aim 1, subjects receiving maxillary dental implants will be randomized to take either naproxen or placebo following surgery, with longitudinal, quantitative data on osseointegration collected by Osstell radiofrequency analysis. In Aim 2, failed implants will be retrieved from subjects who provide NSAID usage information. These specimens will be analyzed using microCT, undecalcfied histology, and protein analysis. Together, our results will quantitatively determine the risks of NSAIDs on dental implant osseointegration.